Evidence map›Paper›PMID 42857313›Full record

ReviewEULAR rheumatology open2026

3D printing in rheumatology.

Samuel Guigo, Sophie Débonnaire, Zoé Rapin, Alain Saraux

Abstract readReview
In one paragraph

Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samuel GuigoW.PRINT, Clinical Research and Innovation Department, Centre Hospitalier Universitaire Brest, Brest, France.
Sophie DébonnaireUniversité de Bretagne Occidentale (Univ Brest), Department of Rheumatology and pole Pharmacie Recherche Santé Publique et Santé au Travail, Centre Hospitalier Universitaire Brest, Institut National de la Santé et de la Recherche Medicale Lymphocytes B, Autoimmunité, Immunothérapies (U1227), LabEx Immunotherapy, Graft, Oncology, Brest, France.
Zoé RapinUniversité de Bretagne Occidentale (Univ Brest), Department of Rheumatology and pole Pharmacie Recherche Santé Publique et Santé au Travail, Centre Hospitalier Universitaire Brest, Institut National de la Santé et de la Recherche Medicale Lymphocytes B, Autoimmunité, Immunothérapies (U1227), LabEx Immunotherapy, Graft, Oncology, Brest, France.
Alain SarauxW.PRINT, Clinical Research and Innovation Department, Centre Hospitalier Universitaire Brest, Brest, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-dimensional (3D) printing, or additive manufacturing, revolutionises medicine by creating customised objects from digital models, layer by layer. In hospitals, technologies like Fused Deposition Modelling (FDM), stereolithography, and laser powder bed fusion are used, each offering unique advantages. Materials range from biocompatible polymers for orthoses to metal alloys for implants. FDM printers are affordable and suitable for prototyping but lack precision. Stereolithography provides high resolution and biocompatibility, ideal for medical devices, though postprocessing is required. PolyJet technology produces high-quality, multicoloured parts but is costly, limiting its use to specialised settings. Applications include anatomical models for preoperative planning, surgical guides, custom orthoses, and implants, enhancing precision and patient outcomes. In education, 3D-printed models aid in training for complex procedures. Research explores regenerative medicine, such as scaffolds for tissue regeneration and drug delivery systems. In rheumatology, 3D printing shows potential for custom orthoses, educational tools, and bioprinting cartilage. However, adoption is limited by methodological, economic, and environmental barriers. Waste production, material strength, and cost remain challenges. Evidence is mostly observational, with few randomised trials. Future prospects include biocompatible materials, improved segmentation techniques, and smartphone-integrated modelling tools. Custom prostheses and 3D-printed medications offer personalised care but require rigorous safety and regulatory frameworks. In conclusion, although 3D printing holds significant promise for rheumatology and the broader medical field, its integration into clinical practice depends on stronger evidence, cost-effectiveness, and sustainable practices. Its development could be advanced through academic initiatives as well as through collaborations with 3D printing firms to conduct formal clinical trials.

Identifiers

PMID42857313
PMCPMC13650355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.